candesartan has been researched along with cardiovascular agents in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Komajda, M | 1 |
| Idikio, H; Jugdutt, BI; Palaniyappan, A; Uwiera, RR | 1 |
| Fang, JC; Oghlakian, GO; Sipahi, I | 1 |
| Abdul-Rahim, AH; Fulton, RL; Jhund, PS; Kjekshus, J; Latini, R; Lees, KR; Lip, GY; Maggioni, AP; McMurray, JJ; Perez, AC; Tavazzi, L; Tognoni, G; Wikstrand, J | 1 |
| Yan, Q; Yang, F; Zhang, L | 1 |
3 review(s) available for candesartan and cardiovascular agents
| Article | Year |
|---|---|
Improving outcomes in chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Drug Therapy, Combination; Heart Failure; Hospitalization; Humans; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Ventricular Function, Left | 2006 |
Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm?
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Calcium Channel Blockers; Cardiovascular Agents; Digitalis Glycosides; Exercise; Exercise Tolerance; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Irbesartan; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Ventricular Dysfunction, Left; Verapamil | 2011 |
Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; Biomarkers; Biphenyl Compounds; Cardiovascular Agents; Diabetes Mellitus, Type 1; Fatty Acids, Omega-3; Female; Fluorobenzenes; Follow-Up Studies; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Proportional Hazards Models; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Stroke; Stroke Volume; Sulfonamides; Tetrazoles | 2015 |
3 other study(ies) available for candesartan and cardiovascular agents
| Article | Year |
|---|---|
ARBs reduce heart-failure deaths, hospitalizations.
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Cardiovascular Agents; Heart Failure; Hospitalization; Humans; Tetrazoles | 2003 |
Comparison of vasopeptidase inhibitor omapatrilat and angiotensin receptor blocker candesartan on extracellular matrix, myeloperoxidase, cytokines, and ventricular remodeling during healing after reperfused myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cardiovascular Agents; Cytokines; Extracellular Matrix; Humans; Isoenzymes; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardial Reperfusion; Myocardium; Nitric Oxide Synthase; Peroxidase; Protease Inhibitors; Pyridines; Random Allocation; Rats; Tetrazoles; Thiazepines; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-3; Ventricular Remodeling | 2009 |
Candesartan ameliorates vascular smooth muscle cell proliferation via regulating miR-301b/STAT3 axis.
Topics: Benzimidazoles; Biphenyl Compounds; Cardiovascular Agents; Cell Proliferation; Cells, Cultured; Down-Regulation; Gene Expression Regulation, Developmental; Humans; MicroRNAs; Muscle, Smooth, Vascular; STAT3 Transcription Factor; Tetrazoles | 2020 |